The DOI matches its Crossref record; 82 of the 82 references it cites were found in a registry or an index.
Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor
Abstract
P-glycoprotein actively transports structurally unrelated compounds out of cells, conferring the multidrug resistance phenotype in cancer. Tariquidar is a potent, specific, noncompetitive inhibitor of P-glycoprotein. Tariquidar inhibits the ATPase activity of P-glycoprotein, suggesting that the modulating effect is derived from the inhibition of substrate binding, inhibition of ATP hydrolysis or both. In clinical trials, tariquidar is tolerable and does not have significant pharmacokinetic interaction with chemotherapy. In patients, inhibition of P-glycoprotein has been demonstrated for 48 h after a single dose of tariquidar. Studies to assess a possible increase in toxicity of chemotherapy and the impact of P-glycoprotein inhibition on tumor response and patient outcome are ongoing. Tariquidar can be considered an ideal agent for testing the role of P-glycoprotein inhibition in cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants
Juliano, R. L., & Ling, V. (1976) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(76)90160-7 · Cited by 3,296
Mechanisms of Cancer Drug Resistance
Gottesman, M. M. (2002) · Annual Review of Medicine · doi:10.1146/annurev.med.53.082901.103929 · Cited by 2,643
The Human ATP-Binding Cassette (ABC) Transporter Superfamily
Dean, M., Rzhetsky, A., & Allikmets, R. (2001) · Genome Research · doi:10.1101/gr.184901 · Cited by 1,748
Expression of a multidrug-resistance gene in human tumors and tissues.
Fojo, A. T., Ueda, K., Slamon, D. J., Poplack, D. G., Gottesman, M. M., & Pastan, I. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.1.265 · Cited by 1,544
The Human ATP-Binding Cassette (ABC) Transporter Superfamily
Dean, M. (2001) · Genome Research · doi:10.1101/gr.gr-1649r · Cited by 1,113
Pharmacology of drugs that alter multidrug resistance in cancer.
Ford, J. M., & Hait, W. N. (1990) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)00045-6 · Cited by 974
Thomas, H., & Coley, H. M. (2003) · Cancer Control · doi:10.1177/107327480301000207 · Cited by 931
Sarkadi, B., Homolya, L., Szakács, G., & Váradi, A. (2006) · Physiological Reviews · doi:10.1152/physrev.00037.2005 · Cited by 726
Increased drug delivery to the brain by P-glycoprotein inhibition
Sadeque, A. (2000) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2000.109156 · Cited by 426
List, A. F., Kopecky, K. J., Willman, C. L., Head, D. R., Persons, D. L., Slovak, M. L., Dorr, R., Karanes, C., Hynes, H. E., Doroshow, J. H., et al. (2001) · Blood · doi:10.1182/blood.v98.12.3212 · Cited by 419
Cited by
Overcoming the Blood–Brain Barrier: The Role of Nanomaterials in Treating Neurological Diseases
Furtado, D., Björnmalm, M., Ayton, S., Bush, A. I., Kempe, K., & Caruso, F. (2018) · Advanced Materials · doi:10.1002/adma.201801362 · Cited by 708
Li, W., Zhang, H., Assaraf, Y. G., Zhao, K., Xu, X., Xie, J., Yang, D.-H., & Chen, Z.-S. (2016) · Drug Resistance Updates · doi:10.1016/j.drup.2016.05.001 · Cited by 673
Szakács, G., Váradi, A., Özvegy-Laczka, C., & Sarkadi, B. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2007.12.010 · Cited by 569
Very important pharmacogene summary
Hodges, L. M., Markova, S. M., Chinn, L. W., Gow, J. M., Kroetz, D. L., Klein, T. E., & Altman, R. B. (2011) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e3283385a1c · Cited by 436
Miller, D. S., Bauer, B., & Hartz, A. M. S. (2008) · Pharmacological Reviews · doi:10.1124/pr.107.07109 · Cited by 392
Modulation of P-glycoprotein efflux pump: induction and activation as a therapeutic strategy
Silva, R., Vilas-Boas, V., Carmo, H., Dinis-Oliveira, R. J., Carvalho, F., de Lourdes Bastos, M., & Remião, F. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.11.013 · Cited by 339
Natural products as multidrug resistance modulators in cancer
Kumar, A., & Jaitak, V. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.05.027 · Cited by 334
Patil, Y., Sadhukha, T., Ma, L., & Panyam, J. (2009) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.01.021 · Cited by 317
Collateral sensitivity as a strategy against cancer multidrug resistance
Pluchino, K. M., Hall, M. D., Goldsborough, A. S., Callaghan, R., & Gottesman, M. M. (2012) · Drug Resistance Updates · doi:10.1016/j.drup.2012.03.002 · Cited by 305
Zhang, H., Xu, H., Ashby, C. R., Assaraf, Y. G., Chen, Z., & Liu, H. (2021) · Medicinal Research Reviews · doi:10.1002/med.21739 · Cited by 270
Nanodrug delivery in reversing multidrug resistance in cancer cells
Yergeri, M., Kapse-Mistry, S., Srivastava, R., & Govender, T. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00159 · Cited by 255
Development of inhibitors of ATP-binding cassette drug transporters – present status and challenges
Shukla, S., Wu, C.-P., & Ambudkar, S. V. (2008) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.4.2.205 · Cited by 253
Blood–Brain Barrier Breakdown in Alzheimer’s Disease: Mechanisms and Targeted Strategies
Alkhalifa, A. E., Al-Ghraiybah, N. F., Odum, J., Shunnarah, J. G., Austin, N., & Kaddoumi, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242216288 · Cited by 212
Genovese, I., Ilari, A., Assaraf, Y. G., Fazi, F., & Colotti, G. (2017) · Drug Resistance Updates · doi:10.1016/j.drup.2017.10.003 · Cited by 156
Lai, J.-I., Tseng, Y.-J., Chen, M.-H., Huang, C.-Y. F., & Chang, P. M.-H. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.561936 · Cited by 144
“Tariquidar is a potent and specific inhibitor of p-gp, acting as an ATPase inhibitor (45).”
BackgroundABC Transporters: Unvalidated Therapeutic Targets in Cancer and the CNS
W. Robey, R., R. Massey, P., Amiri-Kordestani, L., & E. Bates, S. (2010) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152010794473957 · Cited by 85
Breaking Bad: the Structure and Function of the Blood-Brain Barrier in Epilepsy
Han, H., Mann, A., Ekstein, D., & Eyal, S. (2017) · The AAPS Journal · doi:10.1208/s12248-017-0096-2 · Cited by 83
Insights into P-Glycoprotein Inhibitors: New Inducers of Immunogenic Cell Death
Kopecka, J., Godel, M., Dei, S., Giampietro, R., Belisario, D. C., Akman, M., Contino, M., Teodori, E., & Riganti, C. (2020) · Cells · doi:10.3390/cells9041033 · Cited by 41
Metadata
- Authors
- Fox, E., & Bates, S. E.
- Venue
- Expert Review of Anticancer Therapy
- Publisher
- Informa UK Limited
- Published
- 2007-04
- Volume
- 7
- Issue
- 4
- Pages
- 447-459
- ISSN
- 1473-7140 (ISSN-L)
- 1744-8328
- OpenAlex
- W2152546397
- Cited by
- 350
- References
- 82
- FWCI
- 10.11
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.